» Articles » PMID: 26854927

FOXE3 Mutations Predispose to Thoracic Aortic Aneurysms and Dissections

Abstract

The ascending thoracic aorta is designed to withstand biomechanical forces from pulsatile blood. Thoracic aortic aneurysms and acute aortic dissections (TAADs) occur as a result of genetically triggered defects in aortic structure and a dysfunctional response to these forces. Here, we describe mutations in the forkhead transcription factor FOXE3 that predispose mutation-bearing individuals to TAAD. We performed exome sequencing of a large family with multiple members with TAADs and identified a rare variant in FOXE3 with an altered amino acid in the DNA-binding domain (p.Asp153His) that segregated with disease in this family. Additional pathogenic FOXE3 variants were identified in unrelated TAAD families. In mice, Foxe3 deficiency reduced smooth muscle cell (SMC) density and impaired SMC differentiation in the ascending aorta. Foxe3 expression was induced in aortic SMCs after transverse aortic constriction, and Foxe3 deficiency increased SMC apoptosis and ascending aortic rupture with increased aortic pressure. These phenotypes were rescued by inhibiting p53 activity, either by administration of a p53 inhibitor (pifithrin-α), or by crossing Foxe3-/- mice with p53-/- mice. Our data demonstrate that FOXE3 mutations lead to a reduced number of aortic SMCs during development and increased SMC apoptosis in the ascending aorta in response to increased biomechanical forces, thus defining an additional molecular pathway that leads to familial thoracic aortic disease.

Citing Articles

Modeling thoracic aortic genetic variants in the zebrafish: useful for predicting clinical pathogenicity?.

Prendergast A, Sheppard M, Famulski J, Nicoli S, Mukherjee S, Sips P Front Cardiovasc Med. 2025; 12:1480407.

PMID: 40066353 PMC: 11892108. DOI: 10.3389/fcvm.2025.1480407.


Developmental endothelial locus 1: the present and future of an endogenous factor in vessels.

Jiang D, Yue H, Liang W, Wu Z Front Physiol. 2024; 15:1347888.

PMID: 39206385 PMC: 11350114. DOI: 10.3389/fphys.2024.1347888.


Congenital anterior segment ocular disorders: Genotype-phenotype correlations and emerging novel mechanisms.

Reis L, Seese S, Costakos D, Semina E Prog Retin Eye Res. 2024; 102:101288.

PMID: 39097141 PMC: 11392650. DOI: 10.1016/j.preteyeres.2024.101288.


Heritable thoracic aortic disease: a literature review on genetic aortopathies and current surgical management.

Mills A, Sandhu H, Ikeno Y, Tanaka A Gen Thorac Cardiovasc Surg. 2024; 72(5):293-304.

PMID: 38480670 DOI: 10.1007/s11748-024-02017-x.


Inducing aortic aneurysm/dissection in zebrafish: evaluating the efficacy of β-Aminopropionic Nitrile as a model.

Zhang J, Liang Y, Zeng W, Gao X, Wang D, Mai C Anim Cells Syst (Seoul). 2024; 28(1):84-92.

PMID: 38440122 PMC: 10911251. DOI: 10.1080/19768354.2024.2322055.


References
1.
Brownell I, Dirksen M, Jamrich M . Forkhead Foxe3 maps to the dysgenetic lens locus and is critical in lens development and differentiation. Genesis. 2000; 27(2):81-93. DOI: 10.1002/1526-968x(200006)27:2<81::aid-gene50>3.0.co;2-n. View

2.
Zhang W, Geiman D, Shields J, Dang D, Mahatan C, Kaestner K . The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem. 2000; 275(24):18391-8. PMC: 2231805. DOI: 10.1074/jbc.C000062200. View

3.
Saleem R, Banerjee-Basu S, Berry F, Baxevanis A, Walter M . Analyses of the effects that disease-causing missense mutations have on the structure and function of the winged-helix protein FOXC1. Am J Hum Genet. 2001; 68(3):627-41. PMC: 1274476. DOI: 10.1086/318792. View

4.
Semina E, Brownell I, Mintz-Hittner H, Murray J, Jamrich M . Mutations in the human forkhead transcription factor FOXE3 associated with anterior segment ocular dysgenesis and cataracts. Hum Mol Genet. 2001; 10(3):231-6. DOI: 10.1093/hmg/10.3.231. View

5.
Komarov P, Komarova E, Kondratov R, Coon J, Chernov M, Gudkov A . A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285(5434):1733-7. DOI: 10.1126/science.285.5434.1733. View